US equities
|
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
GOOGL
$324.89
▲+1.34%
NVDA
$215.38
▼-1.17%
MSFT
$531.01
▼-0.06%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
SNDK
$1,404.77
▲+7.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Annexon, Inc. - common stock
(NQ:
ANNX
)
4.040
+0.280 (+7.45%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Annexon, Inc. - common stock
< Previous
1
2
3
4
5
Next >
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
October 28, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
September 24, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Participate in Upcoming September Investor Conferences
September 02, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Over Four Decades of Clinical, Scientific and Corporate Leadership Advancing Innovation in Retinal Disease
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
August 06, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
July 14, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Participate in Upcoming June Investor Conferences
May 27, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 07, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present at the Bank of America Securities Health Care Conference 2026
May 06, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 30, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
February 17, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
January 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
January 08, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
November 14, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Annexon Biosciences
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
